A jury has found that a vitamin C manufacturer based in China, as well as its affiliate company, are guilty of price-fixing in the US and have been ordered to pay $162 million. The $54.1 million in damages to the victims of the class action suit were trebled for Hebei Welcome Pharmaceutical Co Ltc, the vitamin C manufacturer. Sources say that the two defendants who were previously part of the case settled out of court for a reported $22.5 million. As CPI previously reported, the defendants had used a rare defense claiming that their company forced them to fix prices abroad, a defense known as the foreign sovereign compulsion doctrine.
Featured News
Tech Policy and Regulation Weekly Roundup
Jan 23, 2026 by
CPI
Perkins Coie Adds Former DOJ Antitrust Leader as Partner in Washington
Jan 22, 2026 by
CPI
Ryanair Boss Dismisses Musk’s Buyout as Starlink Feud Escalates
Jan 22, 2026 by
CPI
Paramount Extends Warner Bros Bid as Netflix Rivalry Heats Up
Jan 22, 2026 by
CPI
South Korea Breaks New Ground With Landmark AI Law
Jan 22, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Recidivism
Jan 21, 2026 by
CPI
Recidivism, Multiple Offending, and Serial Offending in Antitrust
Jan 21, 2026 by
Gregory Werden
Antitrust Recidivism: Why Repeat Cases Appear, and Why True Reoffending Is Rare in the United States
Jan 21, 2026 by
Lisa M. Phelan, Megan S. Golden, Adrienne Irmer & Nina Worth
99 Antitrust Problems – Is Recidivism One?
Jan 21, 2026 by
Brian A. Ratner & Kartik S. Madiraju
Holding A Cat by the Tail: A View of Cartel Recidivism in U.S. Antitrust Enforcement
Jan 21, 2026 by
Mark Rosman & KaDee L. Ru